secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001104659-25-016725
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.02, 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart
--------------------------------------------------------------------------------

- ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).
- 2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.
- Terminated MedImmune license for mavrilimumab; effective May 22, 2025.
- Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.
- Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/0001104659-25-016725-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925016725/tm257489d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-016725

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer